Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00175383 | Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer | completed | N/A | 100 | University of British ColumbiaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01325961 | Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers(RCMI-PELVIS) | completed | N/A | 215 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 2, 2026 |
| clinicaltrials |
| NCT02346253 | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | completed | N/A | 146 | Stanford UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04000880 | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health(AMPLIFY) | completed | N/A | 603 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00183820 | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | completed | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05171387 | Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | completed | Phase 2 | 78 | BayerINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05938270 | A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.(ASCERTAIN) | completed | Phase 1 | 113 | AstraZenecaINDUSTRY | 6 | Jun 30, 2026 | clinicaltrials |
| NCT03285152 | A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients | completed | N/A | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | completed | Phase 1 | 7 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03326713 | Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project(GRACE) | completed | N/A | 668 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04746638 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04817501 | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System(CTCs) | completed | — | 150 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06101927 | Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06359964 | Infective Complications in TP Biopsy Without Antibiotic Prophylaxis | completed | N/A | 1,753 | Chinese University of Hong KongOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06386653 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06874985 | Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation | completed | N/A | 1,264 | International Agency for Research on CancerOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05368207 | Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient(Pemb-HT) | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06660147 | Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer(KELI-PAOLA) | completed | — | 243 | ARCAGY/ GINECO GROUPOTHER | 2 | Jun 23, 2026 | clinicaltrials |
| NCT01802242 | Tumor TARGET Prostate Cancer | completed | N/A | 85 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02854982 | Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer(EPICAP-QALY) | completed | — | 900 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06213571 | Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas | completed | N/A | 80 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655648 | Dual-tracer PET Radiomics for Prostate Cancer Stratification | completed | — | 100 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04751929 | Abemaciclib With or Without Atezolizumab for mCRPC | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05721326 | Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition | completed | N/A | 1,283 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07653191 | Changes in Uterine Artery Resistance Index Following Cervical Conization | completed | N/A | 50 | Adana City Training and Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05617885 | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | completed | Phase 1 | 9 | Praful Ravi, MB BCHir, MRCPOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | completed | Phase 3 | 387 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648745 | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer(CEBOC) | completed | Phase 2 | 30 | Prof Gordon JaysonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648940 | Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients | completed | Phase 1 | 74 | Zodiac Produtos Farmaceuticos S.A.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | completed | Phase 1 / Phase 2 | 46 | Genelux CorporationINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03652493 | Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway(PRO-CARBO) | completed | Phase 2 | 16 | Centre Francois BaclesseOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04463771 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.(POD1UM-204) | completed | Phase 2 | 206 | Incyte CorporationINDUSTRY | 7 | Jun 11, 2026 | clinicaltrials |
| NCT05730712 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06647992 | Effect of Nurse Navigation Program on Cervical Cancer Screening Behaviour of the Women Aged 30-65 | completed | N/A | 80 | TURKAN OZDASOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04027868 | Genomic BRCA and Extensive ovArian Cancer Testing(GREAT) | completed | — | 1,500 | ARCAGY/ GINECO GROUPOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05682950 | Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer | completed | Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2026source: clinicaltrials